Financial Shenanigans

The Forensic Verdict

Convatec sits at the lower edge of Elevated risk. Cash conversion is genuinely strong — five-year CFO is 2.7x reported net income and free cash flow is 1.8x — so management is not inflating economics on a hard-cash basis. The risk lives one layer up: the wedge between reported and "adjusted" earnings has widened sharply (FY2025 adjusted net profit of $358M is more than double reported $175M), all headline growth metrics are framed "ex-InnovaMatrix" after a $72M impairment, transformation costs labelled "one-off" have now recurred for four consecutive years, and FY2025 working capital absorbed $84M of receivables on only 6.5% revenue growth. Auditor change (Deloitte to EY for FY2026) is a planned rotation, not adverse, but lands in the same year as a 32.96% vote against the remuneration policy and an unplanned CEO succession after the death-in-service of Karim Bitar. The single fact that would most change the grade: whether the FY2025 receivables jump reverses in 1H FY2026, or whether it signals channel pressure to defend the adjusted operating profit bonus metric (which paid 100% of max).

The 13-shenanigan scorecard

Breeding Ground

Convatec's governance setup is high-quality on paper but compensation incentives create a clear bias toward the very adjusted metrics that absorb most of the year's accounting noise. The FY2025 annual bonus paid 81.6% of maximum on metrics weighted 40% to adjusted operating profit (constant currency), 25% to organic revenue growth ex-InnovaMatrix, and 15% to free cash flow to equity — the latter two of which are the most definitionally elastic numbers in the report. Adjusted operating profit hit $551M against a maximum hurdle of $550M (the bonus paid 100% on this leg). The 2025 AGM saw 32.96% vote against the remuneration policy and 24.36% vote against the omnibus incentive plan — large opposition for a FTSE 100 issuer. Audit-committee chair Margaret Ewing is a former Deloitte partner; the audit firm has been Deloitte through FY2025 with EY taking over for FY2026 under a planned, board-approved rotation. There is no external evidence of regulatory action, short-seller report, or material weakness.

The pattern: incentive design creates a structural reason to defend adjusted operating profit and FCFE, both of which are management-defined. The board has the right people (Ewing, May, Mason, Coussios), but the compensation architecture would benefit from a reported-EPS or reported-EBIT modifier. The death-in-service of CEO Bitar is not a forensic red flag — it is a tragedy that triggered routine LTI early-vesting under the plan rules — but the fact that it lands in the same FY as the InnovaMatrix impairment, the auditor change, and the working-capital build means a forensic eye should not let any of these wash the others out.

Earnings Quality

Reported earnings are not inflated; they are suppressed by acquired-intangible amortization that management addbacks aggressively. The harder question is whether the cushion that accounting provides is masking softer underlying revenue mechanics in FY2025.

Adjusted-vs-reported wedge has widened

Adjusted net profit was 1.05x reported in FY2022 and is 2.05x in FY2025. The widening is explained almost entirely by the $72M FY2025 InnovaMatrix impairment ($55M after tax) plus stable $130M+ acquired-intangible amortization. Of the FY2025 amortization, $95M relates to intangibles arising from the 2008 spin-out from Bristol-Myers Squibb and will be fully amortised by mid-2026 — meaning roughly $7-8 cents of FY2026 reported EPS will arrive from accounting, not operations. This is a known mechanical effect, but it is not flagged with anything like the prominence it deserves in the FY2025 narrative.

Cash earnings are real

Operating cash flow has run above net income in every year since FY2013. The ratio is mechanical (high non-cash amortization) but it is unambiguously cash-positive: five-year cumulative CFO of $1,821M against cumulative NI of $676M, and FCF of $1,197M. Even after subtracting cumulative acquisitions of $505M, free-cash-flow-after-M&A is $692M — almost 1.0x reported net income across the cycle. That is a green light on cash quality.

Receivables and inventory are the single sharpest yellow flag

Trade receivables grew $84M (25.1%) on revenue growth of 6.6%, opening an 18.5pp gap that is wider than any year since FY2013. Inventory grew $67M (19.2%). Management's MDA attributes the inventory build to "build of inventory" ahead of FY2026 tariff exposure and the receivable rise to "increase in trade receivables". Neither explanation is quantified. The DSO step-up is from 53.3 to 56.4 days — not extreme, but reverses two years of improvement and lands in the year that the 25%-weighted organic-revenue-growth bonus metric paid 74.1% of max. Three benign explanations are plausible (Q4 weighting, FX, distributor mix); a less benign one (terms extension to hit revenue targets) is consistent with the data and cannot be ruled out from the disclosure.

Soft-asset intensity remains high but is moderating

Goodwill and intangibles together still represent 53% of total assets (FY2024: 60%). Goodwill alone is 36% — a level that makes the impairment test the single most important annual judgment area. Deloitte flagged InnovaMatrix as a Key Audit Matter in the FY2025 audit; the test passed only after a $72M write-down. Triad/InnovaMatrix carrying value sits on the balance sheet at a now-reduced level, but the same logic applies to other recent deals (Cure Medical, EuroTec, Symbius) where earn-outs are still being paid five years post-deal — a sign that initial business cases were not all met.

Cash Flow Quality

Convatec is a real cash generator, but FY2025 leans on payables extension rather than receivable collection.

Cash conversion is durable

Cumulative ratios above 1.0x even after M&A is the single most important clean test in this entire report. It rules out gross overstatement of earnings. The amortization addbacks are non-cash and well-established; cash earnings are real.

Working capital flipped from tailwind to headwind

Adjusted working capital was an inflow of $7M in FY2024 (helping that year's $396M CFO) and reverted to a $40M outflow in FY2025. The CFO line still rose to $470M — but the lift came from accounts payable extending from $382M to $493M, a $111M move that is materially larger than the $84M receivable build it offsets. Days payable outstanding lengthened from 140 to 150 days. That is not yet a supplier-finance flag (no programme is disclosed in the MDA), but it is a working-capital lifeline that cannot repeat indefinitely. If FY2026 sees AP normalise and AR stay elevated, headline CFO will compress sharply.

Acquisition-adjusted FCF is the harder test

FY2022 was negative on this measure. The pace of M&A has slowed materially (from $173M FY2022 to $24M FY2025), turning the acquisition-adjusted picture from a real concern into a clean test for the most recent two years. But $27M of earn-outs were paid in FY2025 for prior deals — meaning Convatec is still settling 2020-2022 acquisition consideration through the cash-flow statement under "acquisitions and divestitures", not as adjusting items. That is conservative; flag it as background context, not a red flag.

Metric Hygiene

This is where the forensic concentration sits. Every headline financial KPI has at least one definitional choice that flatters the picture.

The FY2025 gap of $228M is the largest in the dataset and 90% non-cash. That is technically clean disclosure. The forensic concern is direction: reported operating profit declined 2.7% while adjusted operating profit rose 12.2%. Bonus and LTI plans key off the rising line.

What to Underwrite Next

The five items that will move the forensic grade in the next two reporting cycles, in priority order.

1. 1H FY2026 receivables. If trade receivables fall back below $370M (in line with FY2024 year-end) on flat/up revenue, the FY2025 spike was timing and the yellow flag closes. If they stay above $400M, channel dynamics or terms extension is the right read and the grade should move up to High.

2. BMS spin-out amortization roll-off. The $95M of acquired-intangible amortization tied to the 2008 BMS spin-out is fully amortised by mid-2026. Watch how management frames the resulting reported-EPS lift (potentially 4-5¢ on FY2026). The honest disclosure is "mechanical accounting roll-off, not operational growth" — anything weaker is a metric-hygiene downgrade.

3. Adjusting-items cash conversion in FY2026. Management has guided that 2026 cash impact of adjusting items will be "similar to 2024" (~$22M). If the cash component rises sharply or the FY2026 list shows new "transformation" items, the "one-off" taxonomy is broken and the grade moves up.

4. EY's first audit (FY2026). New auditors typically retest critical estimates. Particular focus: goodwill impairment ($1,350M carrying value across acquired CGUs), remaining InnovaMatrix-related intangible, contingent-consideration fair value. Any restatement, key-audit-matter expansion, or critical-accounting-estimate change is a forensic event.

5. InnovaMatrix FY2026 revenue and second impairment risk. Guided to ~$20M (FY2025 $69M, FY2024 $99M). If revenue falls below $15M, a second impairment is plausible. The carrying value after the FY2025 write-down is not separately disclosed; check Note 8 of the FY2025 financial statements for the reduced carrying basis.